Literature DB >> 9272607

The postprandial state and the risk of atherosclerosis.

M Hanefeld1, T Temelkova-Kurktschiev.   

Abstract

The results of the Diabetes Intervention Study indicate that postprandial hyperglycaemia, but not fasting hyperglycaemia, is an independent risk factor for myocardial infarction and total mortality in newly detected non-insulin-dependent diabetes mellitus (NIDDM). Blood pressure and triglyceride levels were also found to be risk factors. Data from patients in the Study to Prevent NIDDM show that patients with impaired glucose tolerance (IGT) have higher fasting levels of triglycerides, and higher fasting and postprandial levels of pro-insulin, insulin, and C-peptide levels, compared with those who have normal glucose tolerance (NGT). Postprandial data at 2 h showed that hyperinsulinaemia was prolonged in subjects with IGT compared with their NGT counterparts. Postprandial pro-insulin levels at 2 h were also increased in subjects with IGT, and were found to have the best discriminating power between subjects with IGT and NGT. Those with IGT also secreted markedly higher levels of insulin, indicated by C-peptide levels, than those with NGT. These data support the possibility that subjects with IGT are at an increased risk of conditions such as atherosclerotic disease, even though they have not developed manifest NIDDM. Intervention with agents that can affect risk factors, such as triglyceride levels and postprandial hyperglycaemia, are expected to reduce the risk of atherosclerosis. One promising agent is acarbose, an antihyperglycaemic drug that significantly reduces postprandial insulin and triglyceride levels and has no effect on leptin levels. The ability of acarbose to improve glycaemic control without the potential for inducing hyperinsulinaemia and weight gain appears to give it an advantage over oral antidiabetic agents such as the sulphonylureas.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9272607     DOI: 10.1002/(sici)1096-9136(199708)14:3+<s6::aid-dia438>3.3.co;2-8

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  12 in total

1.  Interindividual and intraindividual variations in postprandial glycemia peak time complicate precise recommendations for self-monitoring of glucose in persons with type 1 diabetes mellitus.

Authors:  Mette Dencker Johansen; Irene Gjerløv; Jens Sandahl Christiansen; Ole K Hejlesen
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

2.  Glucose metabolism among residents in Shanghai: natural outcome of a 5-year follow-up study.

Authors:  Q Qian; X Li; X Huang; M Fu; Z Meng; M Chen; B Feng
Journal:  J Endocrinol Invest       Date:  2011-07-07       Impact factor: 4.256

3.  Hypoglycemic effect of standardized Chrysanthemum zawadskii ethanol extract in high-fat diet/streptozotocin-induced diabetic mice and rats.

Authors:  Yang-Ji Kim; Hyun-Kyu Kim; Hak Sung Lee
Journal:  Food Sci Biotechnol       Date:  2018-05-26       Impact factor: 2.391

Review 4.  Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.

Authors:  D Giugliano; A Ceriello; E Razzoli; K Esposito
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

5.  Effects of modified biliopancreatic diversion on glucose tolerance of GK rats.

Authors:  Shan-Geng Weng; Bin Zhang; Su Feng; Chang-Guo Xu; Chun-Zhong Lin
Journal:  Obes Surg       Date:  2013-04       Impact factor: 4.129

6.  Rapid 'glycaemic swings' induce nitrosative stress, activate poly(ADP-ribose) polymerase and impair endothelial function in a rat model of diabetes mellitus.

Authors:  E M Horváth; R Benko; L Kiss; M Murányi; T Pék; K Fekete; T Bárány; A Somlai; A Csordás; C Szabo
Journal:  Diabetologia       Date:  2009-03-05       Impact factor: 10.122

Review 7.  Drug therapy of postprandial hyperglycaemia.

Authors:  A D Mooradian; J E Thurman
Journal:  Drugs       Date:  1999-01       Impact factor: 9.546

8.  Is hyperglycemia a cardiovascular risk factor?

Authors:  Frank Pistrosch; Andrea Natali; Markolf Hanefeld
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

9.  Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.

Authors:  Christoph Rosak; Gabriele Mertes
Journal:  Diabetes Metab Syndr Obes       Date:  2012-10-12       Impact factor: 3.168

10.  Soluble CD40 ligand levels in otherwise healthy subjects with impaired fasting glucose.

Authors:  Ilker Tasci; Teoman Dogru; Alper Sonmez; Halil Genc; Selim Kilic; Abdullah Olgun; Mahmut Gok; Gokhan Erdem; Selahattin Erikci
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.